RxDoctor Payments Data

David Hinkle, MD

Neurology · Columbus, OHNPI 1013981430

Payments from drug & device makers

$11,371in general payments, 2019–2025

Across 39 payments — averaging $291.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$4K
  • Acorda Therapeutics, Inc$3K
  • H. Lundbeck A S$3K
  • Medtronic$1K
  • AbbVie$246
  • Neurocrine Biosciences, Inc.$206
  • plus $314 from 5 others

What the payments were for

  • Consulting fees$3,36039%
  • Speaking & faculty fees$2,84433%
  • Travel & lodging$1,13713%
  • Food & beverage$1,28715%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,371 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$267,315
Medicare patients
400
Services billed
21,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$263,724
AustedoDeutetrabenazine14$219,126
RytaryCarbidopa/Levodopa34$58,675
GocovriAmantadine Hcl16$53,537
Carbidopa-Levodopa ErCarbidopa/Levodopa666$44,931
Carbidopa-LevodopaCarbidopa/Levodopa1,127$35,399
InbrijaLevodopa13$32,385
Carbidopa33$14,826
AmantadineAmantadine Hcl145$12,113
Rimantadine Hcl25$11,861
Entacapone55$9,296
Memantine Hcl208$7,887
Midodrine Hcl87$6,215
MyrbetriqMirabegron18$5,749
Rasagiline Mesylate39$4,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$206$263,72431 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$128$59,61250 claims
Acorda Therapeutics, IncInbrija$2,838$32,38513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 702 neurology providers in Ohio.

Other neurology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →